Anixa Biosciences (NASDAQ:ANIX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note published on Tuesday morning, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright also issued estimates for Anixa Biosciences’ FY2024 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.46) EPS.

Separately, EF Hutton Acquisition Co. I upgraded shares of Anixa Biosciences to a strong-buy rating in a research report on Wednesday, August 7th.

Anixa Biosciences Trading Up 1.8 %

Shares of NASDAQ:ANIX opened at $3.48 on Tuesday. The firm has a 50 day moving average of $3.18 and a 200-day moving average of $2.99. The stock has a market capitalization of $111.38 million, a PE ratio of -9.22 and a beta of 0.86. Anixa Biosciences has a 12 month low of $2.14 and a 12 month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, research analysts predict that Anixa Biosciences will post -0.43 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. acquired 21,646 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average cost of $3.06 per share, for a total transaction of $66,236.76. Following the transaction, the director now directly owns 890,754 shares in the company, valued at $2,725,707.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIX. Simplicity Wealth LLC acquired a new position in Anixa Biosciences in the 1st quarter valued at approximately $44,000. Staley Capital Advisers Inc. acquired a new position in Anixa Biosciences in the 1st quarter valued at approximately $31,000. Virtu Financial LLC increased its position in Anixa Biosciences by 47.2% in the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after acquiring an additional 5,183 shares during the period. Nations Financial Group Inc. IA ADV increased its position in Anixa Biosciences by 50.0% in the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after acquiring an additional 7,500 shares during the period. Finally, Concorde Asset Management LLC acquired a new position in Anixa Biosciences in the 2nd quarter valued at approximately $31,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.